This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Philips' (PHG) Launches a Range of New Products at EuroPCR 2022
by Zacks Equity Research
Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.
Community Health (CYH) Boosts Obstetrics Care With Technology
by Zacks Equity Research
Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.
AMN Healthcare's (AMN) New Buyout to Aid Healthcare Staffing
by Zacks Equity Research
AMN Healthcare's (AMN) acquisition of Connetics USA is expected to significantly boost its Nurse and Allied Solutions segment globally.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong performance across the Diabetes Care and EPD businesses is driving the top line for Abbott (ABT).
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
by Zacks Equity Research
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
by Zacks Equity Research
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Here's Why Investors Should Retain Medtronic (MDT) Stock
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.
Here's Why You Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.
Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.
3 Reasons Why AMN Healthcare (AMN) Is a Great Growth Stock
by Zacks Equity Research
AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Here's Why You Should Hold on to CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.
Best Growth Stocks to Buy for May 10th
by Zacks Equity Research
AMN, GEO, and AA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 10, 2022.
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 7.38% and 3.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.